Short answer
Immunome Inc. (IMNM) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$86M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$86M
- −49.3% YoY · −17.3% QoQ
- EPS (diluted)
- −$0.76
- −15.2% YoY · −18.8% QoQ
Source: XBRL data from the Immunome Inc. (IMNM) Q3 2026 10-Q on SEC EDGAR. USD.
Immunome Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales or collaboration revenue
- Net loss $85.8M vs $57.5M YoY, operating loss $90.4M vs $60.1M
- Highest R&D spend IM-1021 at $9.6M, up $6.7M YoY; lowest IM-1617 at $1.6M, down $3.8M
- Cash and equivalents $212.8M, marketable securities $248.7M; operating cash use $181.1M for nine months
- Existing liquidity sufficient for at least 12 months; additional financing needed, with rising development and commercialization costs
Risk Factors
- Newly added: IM-3050 Lu-177 program, limited qualified radioactive-material suppliers delayed its Phase 1 trial
- Regulatory: FDA NDA for varegacestat assigned April 28, 2027 PDUFA date, but approval remains uncertain
- Compliance: EU AI Act exposure, noncompliance penalties up to €35 million or 7% of worldwide annual turnover
- Operational: Diagnostic radiotracer shipment delays impaired IM-3050 Phase 1 trial commencement
- Financial: Accumulated deficit $940.9 million, with cash, equivalents and marketable securities funding at least 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunome Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.